NASDAQ:PHAR Pharming Group (PHAR) Stock Price, News & Analysis $11.21 0.00 (0.00%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$10.75 -0.46 (-4.14%) As of 07:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Pharming Group Stock (NASDAQ:PHAR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pharming Group alerts:Sign Up Key Stats Today's Range$10.65▼$11.6950-Day Range$9.82▼$14.4152-Week Range$9.62▼$21.34Volume39,065 shsAverage Volume16,620 shsMarket Capitalization$793.44 millionP/E Ratio93.42Dividend YieldN/APrice Target$38.67Consensus RatingHold Company Overview Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options. Pharming’s principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling. Ruconest is marketed in the United States, Europe and other international markets, subject to applicable regulatory approvals. The company also commercializes Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome, or APDS, a rare primary immunodeficiency. Joenja was developed by Orchard Therapeutics, which Pharming acquired in 2023, and has expanded Pharming’s rare-disease portfolio beyond hereditary angioedema. Pharming continues to pursue additional indications and geographic approvals for its products through regulatory and commercial activities in North America, Europe and other selected markets.AI Generated. May Contain Errors. Read More Pharming Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScorePHAR MarketRank™: Pharming Group scored higher than 88% of companies evaluated by MarketBeat, and ranked 54th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingPharming Group has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialPharming Group has a consensus price target of $38.67, representing about 244.9% upside from its current price of $11.21.Amount of Analyst CoveragePharming Group has only been the subject of 4 research reports in the past 90 days.Read more about Pharming Group's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth20.00% Earnings GrowthEarnings for Pharming Group are expected to grow by 20.00% in the coming year, from $0.25 to $0.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharming Group is 93.42, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.19.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharming Group is 93.42, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.25.Price to Book Value per Share RatioPharming Group has a P/B Ratio of 2.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pharming Group's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.04% of the float of Pharming Group has been sold short.Short Interest Ratio / Days to CoverPharming Group has a short interest ratio ("days to cover") of 1.44, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharming Group has recently decreased by 65.54%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPharming Group does not currently pay a dividend.Dividend GrowthPharming Group does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.09 News SentimentPharming Group has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Pharming Group this week, compared to 3 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pharming Group insiders have not sold or bought any company stock.Percentage Held by Insiders2.07% of the stock of Pharming Group is held by insiders.Percentage Held by Institutions0.03% of the stock of Pharming Group is held by institutions.Read more about Pharming Group's insider trading history. Receive PHAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHAR Stock News HeadlinesPharming Group Obtains US FDA Nod for Rare Primary Immunodeficiency Drug Joenja2 hours ago | marketscreener.comMPharming Gets FDA Approval for Joenja to Treat APDS in Children Aged 4-11September 11 at 6:01 PM | marketscreener.comMThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.September 14 at 1:00 AM | Reagan Gold Group (Ad)Pharming Gets FDA Approval For Joenja In Children With APDSSeptember 11 at 6:01 PM | rttnews.comFDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.September 11 at 6:01 PM | finance.yahoo.comFDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.September 11 at 3:00 PM | globenewswire.comPharming: Faltering Rare-Disease Franchise With Two Potentially Transformative Late-Stage AssetsSeptember 9, 2026 | seekingalpha.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Consensus Rating of "Hold" by AnalystsSeptember 7, 2026 | americanbankingnews.comSee More Headlines PHAR Stock Analysis - Frequently Asked Questions How have PHAR shares performed this year? Pharming Group's stock was trading at $17.67 at the beginning of 2026. Since then, PHAR shares have decreased by 36.6% and is now trading at $11.21. How were Pharming Group's earnings last quarter? Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) released its quarterly earnings results on Thursday, July, 30th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.06 by $0.04. Pharming Group had a trailing twelve-month return on equity of 3.40% and a net margin of 2.51%. Read the conference call transcript. When did Pharming Group IPO? Pharming Group (PHAR) raised $0 in an initial public offering on Wednesday, December 23rd 2020. The company issued 899,802 shares at a price of $0.00 per share. How do I buy shares of Pharming Group? Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pharming Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharming Group investors own include Pharming Group (PHGUF), Meta Platforms (META), NVIDIA (NVDA), Applied DNA Sciences (APDN), Costco Wholesale (COST). Company Calendar Last Earnings7/30/2026Today9/13/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PHAR's financial health is in the Red zone, according to TradeSmith. PHAR has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PHAR CIK1828316 Webwww.pharming.com Phone31-71-524-7400FaxN/AEmployees407Year Founded1988Price Target and Rating Average Price Target for Pharming Group$38.67 High Price Target$41.00 Low Price Target$37.00 Potential Upside/Downside+244.9%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.12 Trailing P/E Ratio93.42 Forward P/E Ratio44.84 P/E GrowthN/ANet Income$2.85 million Net Margins2.51% Pretax Margin4.31% Return on Equity3.40% Return on Assets1.90% Debt Debt-to-Equity Ratio0.34 Current Ratio3.01 Quick Ratio2.31 Sales & Book Value Annual Sales$376.13 million Price / Sales2.11 Cash Flow$0.20 per share Price / Cash Flow55.90 Book Value$3.95 per share Price / Book2.84Miscellaneous Outstanding Shares70,780,000Free Float69,313,000Market Cap$793.44 million OptionableNot Optionable Beta0.01 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:PHAR) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
